Association of Treatment with Remdesivir and 30-day Hospital Readmissions in Patients Hospitalized with COVID-19.

ABSTRACT:

Background

Since the beginning of COVID-19 pandemic, there has been a widespread use of remdesivir in adults and children. There is little known information about remdesivir's role in reducing 30-day readmissions after hospitalization with COVID-19. This study aimed to determine whether treatment with remdesivir was associated with reduced risk of 30-day readmission after index hospitalization with COVID-19.

Methods

The study was a multi-center cohort study in Rhode Island, USA. Patients included all adults that were discharged after hospital treatment for COVID-19 between April 1^st and December 31^st, 2020. The main study outcomes were length of hospital stay, 30-day readmission, and post-discharge 30 days mortality.

Results

A total of 2,062 pati

SUBMITTER: Finn A 

PROVIDER: S-EPMC8830144 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature